Matching Placebo subcutaneous injection

DRUG2 trials

Sponsors

Minneapolis Heart Institute Foundation, Zhejiang Doer Biologics Co., Ltd.

Conditions

Saphenous Vein Graft AtherosclerosisSevere Hypertriglyceridemia

Phase 3

A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

Not yet recruitingNCT07680829

Zhejiang Doer Biologics Co., Ltd.Severe Hypertriglyceridemia

Start: 2026-08-01End: 2030-10-01Target: 378Updated: 2026-07-06

Phase 4

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

TerminatedNCT03542110

Minneapolis Heart Institute FoundationSaphenous Vein Graft Atherosclerosis

Start: 2018-08-04End: 2020-07-31Updated: 2021-09-16